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A ny complex machine (e.g., washing machine,television, or car) comes with an owner’s man-ual that explains how to use it. Another associ-
ated document, seldom seen by consumers, is a de-
tailed description of all the parts and how they are
connected. We shall call this the blueprint.
Likewise, there are two types of health research.
Some researchers are, in effect, searching for the
“owner’s manual” for the human body—the living
conditions that produce the best health. This research
includes epidemiology, which suggests cause-and-effect
relationships; animal experiments, such as those that
test ideas arising from epidemiology; and human inter-
vention studies, such as controlled trials, which provide
the most reliable evidence. We call this lifestyle re-
search. Like an owner’s manual, it tends to focus on the
prevention of problems. In contrast, other researchers,
the large majority, try to fill in the human “blueprint.”
Blueprint research, often referred to as reductionism
or mechanistic research, includes studies of gene ex-
pression, neurotransmitters, cell adhesion molecules,
and biochemical pathways. The results of this research,
like actual blueprints, often guide treatment.
Which type of research is more useful (per dollar
spent)? Lifestyle research, it seems fair to say, has
produced the lion’s share of useful results.1–3 Consider
coronary heart disease (CHD). In the Nurses’ Health
Study,4 the results suggest that about 80% of the
coronary events could be prevented by lifestyle
changes. For instance, replacement of 5% of energy
from saturated fat with unsaturated fat would reduce
risk by about 40%.5 Vigorous or moderate exercise was
associated with 30% lower risk.4 In the Lyon Diet Heart
Study,6 a randomized clinical trial, a Mediterranean
diet high in n-3 fatty acids caused a 70% reduction in
coronary events. Blueprint research has produced
nothing this impressive. In this arena, its most useful
result has probably been the development of statin
drugs, which lower cholesterol. In randomized trials,
these drugs reduced CHD by about one third.7–11
However, credit for this must be allocated to both types
of research. It was lifestyle research that suggested that
lowering cholesterol would reduce CHD. Moreover, the
expense of statin drugs limits their use to persons at
high risk,12 whereas the changes suggested by lifestyle
research, which cost little, are available to all.
Consider cancer. Lifestyle research has identified
several powerful causative and preventive factors.
Smokers and nonsmokers differ in their rate of lung
cancer by a factor of 10 or more. Van’t Veer et al.13
estimated that if everyone in the Netherlands increased
their intake of fruits and vegetables by 100 grams/day,
cancer rates would fall by about 20%. Whole-grain
consumption is associated with a decrease in risk of one
third.14,15 A randomized study reported a halving in
cancer mortality in subjects taking a selenium supple-
ment,16 supporting what epidemiology and animal
studies had previously suggested.17,18 Again, these im-
provements are available to all, at little cost. Nothing so
useful against cancer has come from blueprint
research.
Consider diabetes. In a study of Americans at high
risk for type 2 diabetes, participants who took met-
formin (the product of blueprint research) reduced
their risk of type 2 diabetes by about 30%. But partici-
pants assigned to intensive lifestyle intervention (based
on lifestyle research, of course) reduced their risk by
about 60%.19
Yet blueprint research has received the lion’s share of
research funding. A rough indication of this is the
number of articles published in each area. We selected
100 papers at random from the latest 1 million articles
in MEDLINE, most of which were published in 2000–
2001. We classified all full papers in any area of health
research (n 28) as either lifestyle or blueprint. Blue-
print papers outnumbered lifestyle papers by a ratio of
5 to 1. Along similar lines, a survey of the Journal of the
American Medical Association and the New England Journal
of Medicine found that articles about treatment far
outnumbered articles about prevention.20
Blueprint research has also received the lion’s share
of intangible resources. The Nobel Prize for medicine
should be given, according to Nobel’s will, to those who
“have conferred the greatest benefit on mankind,” yet
in the last 50 years has never honored lifestyle research.
A particularly conspicuous omission is the discovery
that smoking causes cancer, one of the most beneficial
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health-related discoveries of the last century. The re-
source imbalance has no end in sight, as exemplified by
genomic medicine.
The novelist Vladimir Nabokov wrote that a certain
review of his work seemed to be so exactly wrong that it
would make perfect sense when seen in a mirror.
Likewise, the current situation—the relative allocation
of resources to the two types of research—seems exactly
the opposite of what it should be, at least if health
improvement is the goal.
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